Global Antidiabetic SGLT-2 Inhibitor Market Research Report 2024

Report ID: 1899478 | Published Date: Jan 2025 | No. of Page: 94 | Base Year: 2024 | Rating: 4.9 | Webstory: Check our Web story
Request Sample Report
Pre-Order Enquiry
Request Discount(%) 
1 Antidiabetic SGLT-2 Inhibitor Market Overview
    1.1 Product Overview and Scope of Antidiabetic SGLT-2 Inhibitor
    1.2 Antidiabetic SGLT-2 Inhibitor Segment by Type
        1.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales Growth Rate Comparison by Type (2022-2028)
        1.2.2 Canagliflozin
        1.2.3 Empagliflozin
        1.2.4 Dapagliflozin
        1.2.5 Other
    1.3 Antidiabetic SGLT-2 Inhibitor Segment by Application
        1.3.1 Global Antidiabetic SGLT-2 Inhibitor Sales Comparison by Application: (2022-2028)
        1.3.2 Hospitals
        1.3.3 Clinics
        1.3.4 Other
    1.4 Global Antidiabetic SGLT-2 Inhibitor Market Size Estimates and Forecasts
        1.4.1 Global Antidiabetic SGLT-2 Inhibitor Revenue 2017-2028
        1.4.2 Global Antidiabetic SGLT-2 Inhibitor Sales 2017-2028
        1.4.3 Antidiabetic SGLT-2 Inhibitor Market Size by Region: 2017 Versus 2021 Versus 2028
2 Antidiabetic SGLT-2 Inhibitor Market Competition by Manufacturers
    2.1 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Manufacturers (2017-2022)
    2.2 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Manufacturers (2017-2022)
    2.3 Global Antidiabetic SGLT-2 Inhibitor Average Price by Manufacturers (2017-2022)
    2.4 Manufacturers Antidiabetic SGLT-2 Inhibitor Manufacturing Sites, Area Served, Product Type
    2.5 Antidiabetic SGLT-2 Inhibitor Market Competitive Situation and Trends
        2.5.1 Antidiabetic SGLT-2 Inhibitor Market Concentration Rate
        2.5.2 The Global Top 5 and Top 10 Largest Antidiabetic SGLT-2 Inhibitor Players Market Share by Revenue
        2.5.3 Global Antidiabetic SGLT-2 Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Antidiabetic SGLT-2 Inhibitor Retrospective Market Scenario by Region
    3.1 Global Antidiabetic SGLT-2 Inhibitor Retrospective Market Scenario in Sales by Region: 2017-2022
    3.2 Global Antidiabetic SGLT-2 Inhibitor Retrospective Market Scenario in Revenue by Region: 2017-2022
    3.3 North America Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country
        3.3.1 North America Antidiabetic SGLT-2 Inhibitor Sales by Country
        3.3.2 North America Antidiabetic SGLT-2 Inhibitor Revenue by Country
        3.3.3 U.S.
        3.3.4 Canada
    3.4 Europe Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country
        3.4.1 Europe Antidiabetic SGLT-2 Inhibitor Sales by Country
        3.4.2 Europe Antidiabetic SGLT-2 Inhibitor Revenue by Country
        3.4.3 Germany
        3.4.4 France
        3.4.5 U.K.
        3.4.6 Italy
        3.4.7 Russia
    3.5 Asia Pacific Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Region
        3.5.1 Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Region
        3.5.2 Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Region
        3.5.3 China
        3.5.4 Japan
        3.5.5 South Korea
        3.5.6 India
        3.5.7 Australia
        3.5.8 China Taiwan
        3.5.9 Indonesia
        3.5.10 Thailand
        3.5.11 Malaysia
    3.6 Latin America Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country
        3.6.1 Latin America Antidiabetic SGLT-2 Inhibitor Sales by Country
        3.6.2 Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Country
        3.6.3 Mexico
        3.6.4 Brazil
        3.6.5 Argentina
    3.7 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Market Facts & Figures by Country
        3.7.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country
        3.7.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Country
        3.7.3 Turkey
        3.7.4 Saudi Arabia
        3.7.5 UAE
4 Global Antidiabetic SGLT-2 Inhibitor Historic Market Analysis by Type
    4.1 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2017-2022)
    4.2 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Type (2017-2022)
    4.3 Global Antidiabetic SGLT-2 Inhibitor Price by Type (2017-2022)
5 Global Antidiabetic SGLT-2 Inhibitor Historic Market Analysis by Application
    5.1 Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2017-2022)
    5.2 Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Application (2017-2022)
    5.3 Global Antidiabetic SGLT-2 Inhibitor Price by Application (2017-2022)
6 Key Companies Profiled
    6.1 Pfizer
        6.1.1 Pfizer Corporation Information
        6.1.2 Pfizer Description and Business Overview
        6.1.3 Pfizer Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
        6.1.4 Pfizer Antidiabetic SGLT-2 Inhibitor Product Portfolio
        6.1.5 Pfizer Recent Developments/Updates
    6.2 AstraZeneca
        6.2.1 AstraZeneca Corporation Information
        6.2.2 AstraZeneca Description and Business Overview
        6.2.3 AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
        6.2.4 AstraZeneca Antidiabetic SGLT-2 Inhibitor Product Portfolio
        6.2.5 AstraZeneca Recent Developments/Updates
    6.3 Johnson & Johnson
        6.3.1 Johnson & Johnson Corporation Information
        6.3.2 Johnson & Johnson Description and Business Overview
        6.3.3 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
        6.3.4 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Product Portfolio
        6.3.5 Johnson & Johnson Recent Developments/Updates
    6.4 GlaxoSmithKline
        6.4.1 GlaxoSmithKline Corporation Information
        6.4.2 GlaxoSmithKline Description and Business Overview
        6.4.3 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Product Portfolio
        6.4.5 GlaxoSmithKline Recent Developments/Updates
    6.5 Merck & Co
        6.5.1 Merck & Co Corporation Information
        6.5.2 Merck & Co Description and Business Overview
        6.5.3 Merck & Co Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
        6.5.4 Merck & Co Antidiabetic SGLT-2 Inhibitor Product Portfolio
        6.5.5 Merck & Co Recent Developments/Updates
    6.6 Eli Lilly
        6.6.1 Eli Lilly Corporation Information
        6.6.2 Eli Lilly Description and Business Overview
        6.6.3 Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
        6.6.4 Eli Lilly Antidiabetic SGLT-2 Inhibitor Product Portfolio
        6.6.5 Eli Lilly Recent Developments/Updates
    6.7 Sanofi
        6.6.1 Sanofi Corporation Information
        6.6.2 Sanofi Description and Business Overview
        6.6.3 Sanofi Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
        6.4.4 Sanofi Antidiabetic SGLT-2 Inhibitor Product Portfolio
        6.7.5 Sanofi Recent Developments/Updates
    6.8 Takeda Pharmaceuticals
        6.8.1 Takeda Pharmaceuticals Corporation Information
        6.8.2 Takeda Pharmaceuticals Description and Business Overview
        6.8.3 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
        6.8.4 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Product Portfolio
        6.8.5 Takeda Pharmaceuticals Recent Developments/Updates
    6.9 Novo Nordisk
        6.9.1 Novo Nordisk Corporation Information
        6.9.2 Novo Nordisk Description and Business Overview
        6.9.3 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
        6.9.4 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Product Portfolio
        6.9.5 Novo Nordisk Recent Developments/Updates
    6.10 Servier Laboratories
        6.10.1 Servier Laboratories Corporation Information
        6.10.2 Servier Laboratories Description and Business Overview
        6.10.3 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
        6.10.4 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Product Portfolio
        6.10.5 Servier Laboratories Recent Developments/Updates
    6.11 Boehringer Ingelheim
        6.11.1 Boehringer Ingelheim Corporation Information
        6.11.2 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Description and Business Overview
        6.11.3 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
        6.11.4 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Product Portfolio
        6.11.5 Boehringer Ingelheim Recent Developments/Updates
    6.12 Bristol-Myers Squibb
        6.12.1 Bristol-Myers Squibb Corporation Information
        6.12.2 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Description and Business Overview
        6.12.3 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2017-2022)
        6.12.4 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Product Portfolio
        6.12.5 Bristol-Myers Squibb Recent Developments/Updates
7 Antidiabetic SGLT-2 Inhibitor Manufacturing Cost Analysis
    7.1 Antidiabetic SGLT-2 Inhibitor Key Raw Materials Analysis
       7.1.1 Key Raw Materials
       7.1.2 Key Suppliers of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
    7.3 Manufacturing Process Analysis of Antidiabetic SGLT-2 Inhibitor
    7.4 Antidiabetic SGLT-2 Inhibitor Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
    8.1 Marketing Channel
    8.2 Antidiabetic SGLT-2 Inhibitor Distributors List
    8.3 Antidiabetic SGLT-2 Inhibitor Customers
9 Antidiabetic SGLT-2 Inhibitor Market Dynamics
    9.1 Antidiabetic SGLT-2 Inhibitor Industry Trends
    9.2 Antidiabetic SGLT-2 Inhibitor Market Drivers
    9.3 Antidiabetic SGLT-2 Inhibitor Market Challenges
    9.4 Antidiabetic SGLT-2 Inhibitor Market Restraints
10 Global Market Forecast
    10.1 Antidiabetic SGLT-2 Inhibitor Market Estimates and Projections by Type
        10.1.1 Global Forecasted Sales of Antidiabetic SGLT-2 Inhibitor by Type (2023-2028)
        10.1.2 Global Forecasted Revenue of Antidiabetic SGLT-2 Inhibitor by Type (2023-2028)
    10.2 Antidiabetic SGLT-2 Inhibitor Market Estimates and Projections by Application
        10.2.1 Global Forecasted Sales of Antidiabetic SGLT-2 Inhibitor by Application (2023-2028)
        10.2.2 Global Forecasted Revenue of Antidiabetic SGLT-2 Inhibitor by Application (2023-2028)
    10.3 Antidiabetic SGLT-2 Inhibitor Market Estimates and Projections by Region
        10.3.1 Global Forecasted Sales of Antidiabetic SGLT-2 Inhibitor by Region (2023-2028)
        10.3.2 Global Forecasted Revenue of Antidiabetic SGLT-2 Inhibitor by Region (2023-2028)
11 Research Finding and Conclusion
12 Methodology and Data Source
    12.1 Methodology/Research Approach
        12.1.1 Research Programs/Design
        12.1.2 Market Size Estimation
        12.1.3 Market Breakdown and Data Triangulation
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Author List
    12.4 Disclaimer

List of Tables
    Table 1. Global Antidiabetic SGLT-2 Inhibitor Sales Growth Rate Comparison by Type (2022-2028) & (K Pcs) & (US$ Million)
    Table 2. Global Antidiabetic SGLT-2 Inhibitor Sales Growth Rate Comparison by Application (2022-2028) & (K Pcs) & (US$ Million)
    Table 3. Global Antidiabetic SGLT-2 Inhibitor Market Size by Region (US$ Million) (2017 VS 2021 VS 2028)
    Table 4. Global Antidiabetic SGLT-2 Inhibitor Market Competitive Situation by Manufacturers in 2021
    Table 5. Global Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) of Key Manufacturers (2017-2022)
    Table 6. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Manufacturers (2017-2022)
    Table 7. Global Antidiabetic SGLT-2 Inhibitor Revenue (US$ Million) by Manufacturers (2017-2022)
    Table 8. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Manufacturers (2017-2022)
    Table 9. Global Market Antidiabetic SGLT-2 Inhibitor Average Price (USD/Pcs) of Key Manufacturers (2017-2022)
    Table 10. Manufacturers Antidiabetic SGLT-2 Inhibitor Manufacturing Sites and Area Served
    Table 11. Manufacturers Antidiabetic SGLT-2 Inhibitor Product Type
    Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 13. Global Antidiabetic SGLT-2 Inhibitor by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Antidiabetic SGLT-2 Inhibitor as of 2021)
    Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
    Table 15. Global Antidiabetic SGLT-2 Inhibitor Sales by Region (2017-2022) & (K Pcs)
    Table 16. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2017-2022)
    Table 17. Global Antidiabetic SGLT-2 Inhibitor Revenue by Region (2017-2022) & (US$ Million)
    Table 18. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2017-2022)
    Table 19. North America Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2022) & (K Pcs)
    Table 20. North America Antidiabetic SGLT-2 Inhibitor Sales Market Share by Country (2017-2022)
    Table 21. North America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2022) & (US$ Million)
    Table 22. North America Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Country (2017-2022)
    Table 23. Europe Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2022) & (K Pcs)
    Table 24. Europe Antidiabetic SGLT-2 Inhibitor Sales Market Share by Country (2017-2022)
    Table 25. Europe Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2022) & (US$ Million)
    Table 26. Europe Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Country (2017-2022)
    Table 27. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales by Region (2017-2022) & (K Pcs)
    Table 28. Asia Pacific Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2017-2022)
    Table 29. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue by Region (2017-2022) & (US$ Million)
    Table 30. Asia Pacific Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2017-2022)
    Table 31. Latin America Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2022) & (K Pcs)
    Table 32. Latin America Antidiabetic SGLT-2 Inhibitor Sales Market Share by Country (2017-2022)
    Table 33. Latin America Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2022) & (US$ Million)
    Table 34. Latin America Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Country (2017-2022)
    Table 35. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales by Country (2017-2022) & (K Pcs)
    Table 36. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Market Share by Country (2017-2022)
    Table 37. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue by Country (2017-2022) & (US$ Million)
    Table 38. Middle East and Africa Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Country (2017-2022)
    Table 39. Global Antidiabetic SGLT-2 Inhibitor Sales by Type (2017-2022) & (K Pcs)
    Table 40. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type (2017-2022)
    Table 41. Global Antidiabetic SGLT-2 Inhibitor Revenue by Type (2017-2022) & (US$ Million)
    Table 42. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Type (2017-2022)
    Table 43. Global Antidiabetic SGLT-2 Inhibitor Price by Type (2017-2022) & (USD/Pcs)
    Table 44. Global Antidiabetic SGLT-2 Inhibitor Sales (K Pcs) by Application (2017-2022)
    Table 45. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2017-2022)
    Table 46. Global Antidiabetic SGLT-2 Inhibitor Revenue by Application (2017-2022) & (US$ Million)
    Table 47. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Application (2017-2022)
    Table 48. Global Antidiabetic SGLT-2 Inhibitor Price by Application (2017-2022) & (USD/Pcs)
    Table 49. Pfizer Corporation Information
    Table 50. Pfizer Description and Business Overview
    Table 51. Pfizer Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 52. Pfizer Antidiabetic SGLT-2 Inhibitor Product
    Table 53. Pfizer Recent Developments/Updates
    Table 54. AstraZeneca Corporation Information
    Table 55. AstraZeneca Description and Business Overview
    Table 56. AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 57. AstraZeneca Antidiabetic SGLT-2 Inhibitor Product
    Table 58. AstraZeneca Recent Developments/Updates
    Table 59. Johnson & Johnson Corporation Information
    Table 60. Johnson & Johnson Description and Business Overview
    Table 61. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 62. Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Product
    Table 63. Johnson & Johnson Recent Developments/Updates
    Table 64. GlaxoSmithKline Corporation Information
    Table 65. GlaxoSmithKline Description and Business Overview
    Table 66. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 67. GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Product
    Table 68. GlaxoSmithKline Recent Developments/Updates
    Table 69. Merck & Co Corporation Information
    Table 70. Merck & Co Description and Business Overview
    Table 71. Merck & Co Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 72. Merck & Co Antidiabetic SGLT-2 Inhibitor Product
    Table 73. Merck & Co Recent Developments/Updates
    Table 74. Eli Lilly Corporation Information
    Table 75. Eli Lilly Description and Business Overview
    Table 76. Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 77. Eli Lilly Antidiabetic SGLT-2 Inhibitor Product
    Table 78. Eli Lilly Recent Developments/Updates
    Table 79. Sanofi Corporation Information
    Table 80. Sanofi Description and Business Overview
    Table 81. Sanofi Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 82. Sanofi Antidiabetic SGLT-2 Inhibitor Product
    Table 83. Sanofi Recent Developments/Updates
    Table 84. Takeda Pharmaceuticals Corporation Information
    Table 85. Takeda Pharmaceuticals Description and Business Overview
    Table 86. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 87. Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Product
    Table 88. Takeda Pharmaceuticals Recent Developments/Updates
    Table 89. Novo Nordisk Corporation Information
    Table 90. Novo Nordisk Description and Business Overview
    Table 91. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 92. Novo Nordisk Antidiabetic SGLT-2 Inhibitor Product
    Table 93. Novo Nordisk Recent Developments/Updates
    Table 94. Servier Laboratories Corporation Information
    Table 95. Servier Laboratories Description and Business Overview
    Table 96. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 97. Servier Laboratories Antidiabetic SGLT-2 Inhibitor Product
    Table 98. Servier Laboratories Recent Developments/Updates
    Table 99. Boehringer Ingelheim Corporation Information
    Table 100. Boehringer Ingelheim Description and Business Overview
    Table 101. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 102. Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Product
    Table 103. Boehringer Ingelheim Recent Developments/Updates
    Table 104. Bristol-Myers Squibb Corporation Information
    Table 105. Bristol-Myers Squibb Description and Business Overview
    Table 106. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2017-2022)
    Table 107. Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Product
    Table 108. Bristol-Myers Squibb Recent Developments/Updates
    Table 109. Production Base and Market Concentration Rate of Raw Material
    Table 110. Key Suppliers of Raw Materials
    Table 111. Antidiabetic SGLT-2 Inhibitor Distributors List
    Table 112. Antidiabetic SGLT-2 Inhibitor Customers List
    Table 113. Antidiabetic SGLT-2 Inhibitor Market Trends
    Table 114. Antidiabetic SGLT-2 Inhibitor Market Drivers
    Table 115. Antidiabetic SGLT-2 Inhibitor Market Challenges
    Table 116. Antidiabetic SGLT-2 Inhibitor Market Restraints
    Table 117. Global Antidiabetic SGLT-2 Inhibitor Sales Forecast by Type (2023-2028) & (K Pcs)
    Table 118. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share Forecast by Type (2023-2028)
    Table 119. Global Antidiabetic SGLT-2 Inhibitor Revenue Forecast by Type (2023-2028) & (US$ Million)
    Table 120. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share Forecast by Type (2023-2028)
    Table 121. Global Antidiabetic SGLT-2 Inhibitor Sales Forecast by Application (2023-2028) & (K Pcs)
    Table 122. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share Forecast by Application (2023-2028)
    Table 123. Global Antidiabetic SGLT-2 Inhibitor Revenue Forecast by Application (2023-2028) & (US$ Million)
    Table 124. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share Forecast by Application (2023-2028)
    Table 125. Global Antidiabetic SGLT-2 Inhibitor Sales Forecast by Region (2023-2028) & (K Pcs)
    Table 126. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share Forecast by Region (2023-2028)
    Table 127. Global Antidiabetic SGLT-2 Inhibitor Revenue Forecast by Region (2023-2028) & (US$ Million)
    Table 128. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share Forecast by Region (2023-2028)
    Table 129. Research Programs/Design for This Report
    Table 130. Key Data Information from Secondary Sources
    Table 131. Key Data Information from Primary Sources
List of Figures
    Figure 1. Product Picture of Antidiabetic SGLT-2 Inhibitor
    Figure 2. Global Antidiabetic SGLT-2 Inhibitor Market Share by Type in 2021 & 2028
    Figure 3. Canagliflozin Product Picture
    Figure 4. Empagliflozin Product Picture
    Figure 5. Dapagliflozin Product Picture
    Figure 6. Other Product Picture
    Figure 7. Global Antidiabetic SGLT-2 Inhibitor Market Share by Application in 2021 & 2028
    Figure 8. Hospitals
    Figure 9. Clinics
    Figure 10. Other
    Figure 11. Global Antidiabetic SGLT-2 Inhibitor Revenue, (US$ Million), 2017 VS 2021 VS 2028
    Figure 12. Global Antidiabetic SGLT-2 Inhibitor Market Size (2017-2028) & (US$ Million)
    Figure 13. Global Antidiabetic SGLT-2 Inhibitor Sales (2017-2028) & (K Pcs)
    Figure 14. Antidiabetic SGLT-2 Inhibitor Sales Share by Manufacturers in 2021
    Figure 15. Global Antidiabetic SGLT-2 Inhibitor Revenue Share by Manufacturers in 2021
    Figure 16. The Global 5 and 10 Largest Antidiabetic SGLT-2 Inhibitor Players: Market Share by Revenue in 2021
    Figure 17. Antidiabetic SGLT-2 Inhibitor Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2017 VS 2021
    Figure 18. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region (2017-2022)
    Figure 19. Global Antidiabetic SGLT-2 Inhibitor Sales Market Share by Region in 2021
    Figure 20. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region (2017-2022)
    Figure 21. Global Antidiabetic SGLT-2 Inhibitor Revenue Market Share by Region in 2021
    Figure 22. U.S. Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 23. Canada Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 24. Germany Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 25. France Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 26. U.K. Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 27. Italy Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 28. Russia Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 29. China Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 30. Japan Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 31. South Korea Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 32. India Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 33. Australia Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 34. China Taiwan Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 35. Indonesia Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 36. Thailand Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 37. Malaysia Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 38. Mexico Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 39. Brazil Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 40. Argentina Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 41. Turkey Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 42. Saudi Arabia Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 43. UAE Antidiabetic SGLT-2 Inhibitor Revenue Growth Rate (2017-2022) & (US$ Million)
    Figure 44. Sales Market Share of Antidiabetic SGLT-2 Inhibitor by Type (2017-2022)
    Figure 45. Manufacturing Cost Structure of Antidiabetic SGLT-2 Inhibitor
    Figure 46. Manufacturing Process Analysis of Antidiabetic SGLT-2 Inhibitor
    Figure 47. Antidiabetic SGLT-2 Inhibitor Industrial Chain Analysis
    Figure 48. Channels of Distribution
    Figure 49. Distributors Profiles
    Figure 50. Bottom-up and Top-down Approaches for This Report
    Figure 51. Data Triangulation
    Figure 52. Key Executives Interviewed
Please ask for List of Figures. Request Sample Report
Companies Included in Reports:
Pfizer
AstraZeneca
Johnson & Johnson
GlaxoSmithKline
Merck & Co
Eli Lilly
Sanofi
Takeda Pharmaceuticals
Novo Nordisk
Servier Laboratories
Boehringer Ingelheim
Bristol-Myers Squibb
Frequently Asked Questions
Antidiabetic SGLT-2 Inhibitor report offers great insights of the market and consumer data and their interpretation through various figures and graphs. Report has embedded global market and regional market deep analysis through various research methodologies. The report also offers great competitor analysis of the industries and highlights the key aspect of their business like success stories, market development and growth rate.
Antidiabetic SGLT-2 Inhibitor report is categorised based on following features:
  1. Global Market Players
  2. Geopolitical regions
  3. Consumer Insights
  4. Technological advancement
  5. Historic and Future Analysis of the Market
Antidiabetic SGLT-2 Inhibitor report is designed on the six basic aspects of analysing the market, which covers the SWOT and SWAR analysis like strength, weakness, opportunity, threat, aspirations and results. This methodology helps investors to reach on to the desired and correct decision to put their capital into the market.

Related Reports

Flat Engines

The research report includes specific segments by region (country), by manufacturers, by Type and ... Read More

Flat Boxer Engines

The research report includes specific segments by region (country), by manufacturers, by Type and ... Read More